Immunicum’s CEO, Jamal El-Mosleh, holds a company presentation at Sweden Bio’s Life Science Investment Day Scandinavia 2011.
The European Patent Office (EPO) notifies Immunicum that it accepts the claims stated in the patent application 03… Read more
Immunicum welcomes Agneta Edberg as new Chairman of the Board and thanks Olle Stenberg for his previous contribution… Read more
Immunicum receives 3 500 000 SEK from “The Swedish Governmental Agency for Innovation Systems’” (VINNOVA’s) program “Innovations for… Read more
Immunicum welcomes renowned professor Rolf Kiessling as member of the company’s Scientific Advisory Board. Rolf Kiessling, MD, PhD,… Read more
Immunicum reports encouraging data from its INTUVAX proof-of-principle rat study. The main objective of the study was to investigate… Read more
Immunicum raises 6 000 000 SEK in new capital in an oversubscribed new share issue to cover expenses… Read more
Immunicum’s CSO Alex Karlsson-Parra is invited to speak at Sahlgrenska KITM’s and the Swedish Association of Transfusional Medicine’s… Read more
Immunicum has a Scientific Advice Meeting with the Medical Products Agency to discuss its pre-clinical program.
Immunicum submits a new patent application, IMPROVED COMPOSITION FOR INHIBITING TUMOR CELL PROLIFERATION, application number: 1050133-6.